Skip to main content
Clinical Trials/NCT03326089
NCT03326089
Completed
Not Applicable

Short and Long-term Effects of Oxygen Supplemented Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis

Corfu General Hospital1 site in 1 country20 target enrollmentJune 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Idiopathic Pulmonary Fibrosis
Sponsor
Corfu General Hospital
Enrollment
20
Locations
1
Primary Endpoint
6 Minute Walk Test Distance (6MWTD) (meters)
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This is an interventional double-blind randomized controlled trial, to investigate the short and long-term effects of a supervised exercise training program in patients with IPF, depending on alternate patterns of oxygen supplementation during PR.

Detailed Description

The investigators hypothesize that PR service with supplemented oxygen supply regardless of hypoxemia may have significantly better short-term effects in patients with IPF. The study will take place in Corfu General Hospital, by the Departments of Pulmonary Medicine and Physiotherapy and Rehabilitation, respectively. Study participants will be divided in two equal arms 1:1 in a double-blind manner. One of the investigators blinded to their clinical data will assign each participant to PR service either i) with constant supplementary oxygen supply FiO2 50% regardless of saturation status Group A) or ii) without oxygen supply unless upon resting or exercise induced hypoxemia (saturation \<88%) (Group B).

Registry
clinicaltrials.gov
Start Date
June 1, 2017
End Date
August 28, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Corfu General Hospital
Responsible Party
Principal Investigator
Principal Investigator

Ilias Papanikolaou

Consultant Pulmonary Physician

Corfu General Hospital

Eligibility Criteria

Inclusion Criteria

  • diagnosis of IPF based on current established criteria
  • no exacerbation previous 3 months
  • no participation in such program previous 3 months.
  • If on treatment with pirfenidone or nintedanib, this will be recorded and patient should be on treatment for at least 3-6 months to achieve stable state.

Exclusion Criteria

  • concomitant diagnosis of congestive heart failure and lung cancer.

Outcomes

Primary Outcomes

6 Minute Walk Test Distance (6MWTD) (meters)

Time Frame: 2 months

Statistically significant short term effect on exercise capacity

Hospital Anxiety and Depression Scale (HADS) (units on scale)

Time Frame: 2 months

Statistically significant short term effect on health related quality of life

Saint-George Respiratory Questionnaire Idiopathic Pulmonary Fibrosis Version (SGRQ-I) (units on scale)

Time Frame: 2 months

Statistically significant short term effect on health related quality of life

Secondary Outcomes

  • 6 Minute Walk Test Distance (6MWTD) (meters)(12 months)
  • Saint-George Respiratory Questionnaire Idiopathic Pulmonary Fibrosis Version (SGRQ-I) (units on scale)(12 months)
  • Hospital Anxiety and Depression Scale (HADS) (units on scale)(12 months)

Study Sites (1)

Loading locations...

Similar Trials